- support
- info@evidentic.com
- +49 (0) 30 959 99 8831
Menu
Non-small-cell lung carcinoma (NSCLC) accounts for approximately 80 to 85% of lung cancers. The major subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. These subtypes, which arise from different types of lung cells, are grouped together as NSCLC because their treatment and prognosis are often similar. The main risk factors are smoking or exposure to secondhand smoke, exposure to asbestos, exposure to various types of radiation, or a family history of lung cancer.
Showing 1–12 of 40 results
ProductBatch | Antigen | Molecular Class | Drug Brand | Product Concentration | CoA | Quantity per vial | Storage Temperature | Expiry Date | Price from | |
|---|---|---|---|---|---|---|---|---|---|---|
EGFR , MET |
Bispecific Antibody |
Rybrevant® |
50 mg/ml |
– |
7 mg |
-80°C |
2027.04 |
376,00 € |
||
PD-L1 |
Monoclonal Antibody-Fc engineered |
Tecentriq® |
60 mg/mL |
yes |
12 mg |
-80°C |
2022.03 |
301,00 € |
||
PD-L1 |
Monoclonal Antibody-Fc engineered |
Tecentriq® |
60 mg/mL |
yes |
12 mg |
-80°C |
2023.05 |
301,00 € |
||
VEGF-A |
Monoclonal Antibody |
Avastin® |
25 mg/mL |
– |
2 mg |
-80°C |
2018.06 |
212,00 € |
||
VEGF-A |
Monoclonal Antibody |
Avastin® |
25 mg/mL |
– |
2 mg |
-80°C |
2018.09 |
212,00 € |
||
VEGF-A |
Monoclonal Antibody |
Avastin® |
25 mg/mL |
– |
2 mg |
-80°C |
2018.09 |
212,00 € |
||
VEGF-A |
Monoclonal Antibody |
Avastin® |
25 mg/mL |
– |
2 mg |
-80°C |
2018.12 |
212,00 € |
||
VEGF-A |
Monoclonal Antibody |
Avastin® |
25 mg/mL |
– |
2 mg |
-80°C |
2019.03 |
212,00 € |
||
VEGF-A |
Monoclonal Antibody |
Avastin® |
25 mg/mL |
– |
2 mg |
-80°C |
2019.08 |
212,00 € |
||
VEGF-A |
Monoclonal Antibody |
Avastin® |
25 mg/mL |
– |
2 mg |
-80°C |
2019.10 |
212,00 € |
||
VEGF-A |
Monoclonal Antibody |
Avastin® |
25 mg/mL |
yes |
2 mg |
-80°C |
2021.03 |
212,00 € |
||
VEGF-A |
Monoclonal Antibody |
Avastin® |
25 mg/mL |
– |
3 mg |
-80°C |
2017.09 |
267,00 € |
||
VEGF-A |
Monoclonal Antibody |
Avastin® |
25 mg/mL |
– |
3 mg |
-80°C |
2018.03 |
267,00 € |
||
VEGF-A |
Monoclonal Antibody |
Avastin® |
25 mg/mL |
– |
12.5 mg |
-80°C |
2024.06 |
456,00 € |
||
VEGF-A |
Monoclonal Antibody |
Avastin® |
25 mg/mL |
yes |
2 mg |
-80°C |
2024.07 |
212,00 € |
||
PD-L1 |
Monoclonal Antibody |
Imfinzi® |
50 mg/mL |
– |
2 mg |
-80°C |
2021.10 |
218,00 € |
||
CTLA-4 |
Monoclonal Antibody |
Yervoy® |
5 mg/mL |
yes |
2 mg |
-80°C |
2024.09 |
874,00 € |
||
CTLA-4 |
Monoclonal Antibody |
Yervoy® |
5 mg/mL |
yes |
2 mg |
-80°C |
2021.08 |
874,00 € |
||
PD-1 |
Monoclonal Antibody |
Opdivo® |
10 mg/mL |
– |
2 mg |
-80°C |
2024.08 |
307,00 € |
||
PD-1 |
Monoclonal Antibody |
Opdivo® |
10 mg/mL |
– |
2 mg |
-80°C |
2025.05 |
316,00 € |
||
PD-1 |
Monoclonal Antibody |
Opdivo® |
10 mg/mL |
– |
2 mg |
-80°C |
2025.03 |
316,00 € |
||
PD-1 |
Monoclonal Antibody |
Opdivo® |
10 mg/mL |
– |
2 mg |
-80°C |
2018.08 |
316,00 € |
||
PD-1 |
Monoclonal Antibody |
Opdivo® |
10 mg/mL |
– |
2 mg |
-80°C |
2018.10 |
316,00 € |
||
PD-1 |
Monoclonal Antibody |
Opdivo® |
10 mg/mL |
– |
2 mg |
-80°C |
2018.02 |
316,00 € |
||
PD-1 |
Monoclonal Antibody |
Opdivo® |
10 mg/mL |
– |
2 mg |
-80°C |
2019.05 |
316,00 € |
||
PD-1 |
Monoclonal Antibody |
Opdivo® |
10 mg/mL |
– |
2 mg |
-80°C |
2019.01 |
316,00 € |
||
PD-1 |
Monoclonal Antibody |
Opdivo® |
10 mg/mL |
– |
2 mg |
-80°C |
2020.09 |
316,00 € |
||
PD-1 |
Monoclonal Antibody |
Opdivo® |
10 mg/mL |
– |
2 mg |
-80°C |
2020.11 |
316,00 € |
||
PD-1 |
Monoclonal Antibody |
Opdivo® |
10 mg/mL |
– |
2 mg |
-80°C |
2021.02 |
316,00 € |
||
PD-1 |
Monoclonal Antibody |
Keytruda® |
25 mg/mL |
– |
2 mg |
-80°C |
2018.07 |
517,00 € |
Evidentic GmbH
Am Mühlenberg 10
14476 Potsdam | Germany
